Novo Nordisk Launches Oral Ozempic in US Diabetes Market
- nuaxia
- May 6
- 1 min read
First oral GLP-1 tablet expands cardiovascular-protected diabetes treatment beyond injectable semaglutide
Novo Nordisk has launched Ozempic as an oral GLP-1 pill in the US for adults with type 2 diabetes, marking a major expansion of semaglutide into tablet form with added cardiovascular risk reduction benefits.
The treatment will be widely distributed across US pharmacies and offers a new non-injectable option for patients managing both blood sugar and cardiovascular risk.
Alert Type | Drug Approval |
Drug/Device Name | Ozempic oral pill (semaglutide) |
Indication | Type 2 diabetes in adults, including cardiovascular risk reduction (MACE prevention) |
Therapy Area(s) | Endocrinology, Metabolic Disease, Cardiovascular Risk |
Geography | United States (FDA) |
What Changed | Novo Nordisk has launched Ozempic as an oral GLP-1 tablet in the US for type 2 diabetes, offering both glycaemic control and cardiovascular risk reduction. The therapy will be distributed nationwide and produced entirely in the US, with multiple dose options and pharmacy access across 70,000 locations. |
Clinical Relevance | Provides a new oral GLP-1 option with proven cardiovascular benefit, expanding treatment choice beyond injectable semaglutide and supporting earlier intervention in high-risk type 2 diabetes patients. |
Source Link | |
Date | May 2026 |
Status | Draft |
Notes | First oral peptide GLP-1 in the US approved for both glycaemic control and cardiovascular risk reduction. Builds on prior Rybelsus formulation and injectable Ozempic. Pricing varies from ~$25 insured to $149–$299 self-pay. Further 25mg tablet submission under FDA review with decision expected end of 2026. |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Comments